PODD Insulet Corporation

$PODD Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $1.99 up 60.48% YoY • Reported revenue of $842M up 19.21% YoY • Insulets FY 2026 total revenue growth guidance is 21% - 22% in constant currency; adjusted operating margin guidance is ~150 bps YoY expansion, from ~100 bps, and adjusted EPS growth is >30%.

$PODD - Built a large position in PODD over the last few months. The chart alone gives me hope. Plan to hold for the next 3 years.

$PODD 🚨 BULLISH WEDGE BREAKOUT | STRONG Q3 EARNINGS BEAT & $1B BUYBACK 🚨 $PODD is executing a clean 1W trendline breakout off its $145.00 – $160.00 Institutional Buy Zone! High-volume accumulation pushing toward $185.00 – $210.00 Resistance following Q3 earnings. 📊 CHART ZONES & BX ($PODD, 1W): • Smart Money Sell: $320.00 – $350.00 • Institutional Sell: $245.00 – $275.00 • Reclaim Target: $185.00 – $210.00 (CURRENT PUSH) • Institutional Buy: $145.00 – $160.00 (BREAKOUT BASE) • Smart Money Buy: $125.00 – $138.00 • BX Info: Monthly BX -21.9 ▲ | Weekly BX -13.0 ▲ (Strong expansion) 🎯 KEY LEVELS: 🐂 Bull Trigger: Defend $145.00, clear $185.00 to confirm daily structure & target $245.00+. 🐻 Bear Trigger: Weekly close below $125.00. BIAS: Bullish Trendline Breakout / Base Accumulation 📊📈 #hovdid

$PODD 11/20 $155 call seeing nearly $1M in net buying. Reporting earnings on the morning of November 4th. ±12.15 implied move.

$PODD Gross margin hit 75.1 percent in Q3, up from 72.2 percent a year ago, and 90 basis points of that jump came from adjusting the warranty accrual tied to this year's voluntary device corrections, after fewer Pods needed replacing than first estimated. Cash went the other way in the filing. Nine month free cash flow was 211.7 million dollars vs 329.5 million a year ago, while inventories are up 22 percent since year end and receivables up 33 percent.

Anvesti closed a long position $PODD 🟢 +18.51% $138.53 → $164.18 Model: ml_model_v3 · Score: 82.6 Reason: Profit Target · 14 days

$PODD reported earnings before the open today. Adjusted EPS beat estimates: $1.99 vs. $1.59 expected, according to Stock Meadow.

🎯 $PODD | BULLISH SETUP Healthcare / Medical Devices & Supplies 🐂 ⭐ Setup Quality Grade: A- 📌 Grade Justification: • Profitability: Premier Diabetes Tech Operator (~$10.4B market cap, $3.17B+ annual revenue, strong ~23.5% YoY top-line growth). • Revenue Growth: Omnipod 5 international rollout & expanding Type 2 diabetes label clearance driving strong recurring pod sales. • Technical Setup: A- Grade Cleanliness (1W long-term support retest holding $142.19–$149.34 spot right on top of major volume point of control). • Wall St Target: +25%–35%+ Upside ($180.90–$195.40+ consensus price targets). 🏬 Profile: Leading developer, manufacturer, and distributor of tubeless wearable insulin delivery platforms worldwide.#podd #optionsflow #hovdid